Effect of compound kushen injection on immune function in patients with colorectal cancer: a systematic review and meta-analysis DOI Creative Commons
Lixin Zhang,

Guangyan Wei,

Kaiping Wang

и другие.

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Апрель 3, 2025

Colorectal cancer (CRC) is one of the most common malignant tumors worldwide. Chemotherapy and radiotherapy remain cornerstone treatments; however, they often lead to significant immune suppression an increased risk infection. Enhancing function in CRC patients critical for improving clinical outcomes prognosis. To evaluate effects Compound Kushen Injection (CKI) on its role mitigating chemotherapy-induced adverse with CRC. We retrieved randomized controlled trials (RCTs) evaluating CKI from eight Chinese English databases, up until 31 December 2024. The Cochrane Handbook was used assess quality included studies. For meta-analysis, we utilized Review Manager 5.4.1 software. Sensitivity analysis publication bias assessment were conducted using Stata 17.0 A total 2,663 (1,550 males 1,113 females) 30 RCTs included. Compared conventional chemotherapy (CC), combination CC significantly enhanced function, increasing CD3+ levels (MD = 6.15, 95% CI: 4.78 7.53, p < 0.00001), CD4+ 8.05, 6.99 9.11, CD4+/CD8+ 0.36, 0.28 0.44, NK cell 3.60, 2.85 4.34, while reducing CD8+ -4.19, -5.11 -3.27, 0.00001). also improved objective response rate (ORR, RR 1.50, 1.38 1.62, 0.00001) disease control (DCR, 1.15, 1.10 1.19, decreased CEA -1.79, -2.81 -0.76, 0.0007) CA199 -0.73, -1.35 -0.12, 0.02), reduced reactions, including nausea, vomiting, hepatic dysfunction, myelosuppression, neurotoxicity, leukopenia, thrombocytopenia, mouth ulcers. Current evidence suggests that may have beneficial ORR, DCR, reactions patients. However, given variability study absence stage stratification, these findings should be interpreted caution. Furthermore, lack long-term follow-up data limits understanding CKI's impact survival life. High-quality, large-scale extended are needed further efficacy, safety, applicability management. https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=632516, identifier CRD42025632516.

Язык: Английский

Effect of compound kushen injection on immune function in patients with colorectal cancer: a systematic review and meta-analysis DOI Creative Commons
Lixin Zhang,

Guangyan Wei,

Kaiping Wang

и другие.

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Апрель 3, 2025

Colorectal cancer (CRC) is one of the most common malignant tumors worldwide. Chemotherapy and radiotherapy remain cornerstone treatments; however, they often lead to significant immune suppression an increased risk infection. Enhancing function in CRC patients critical for improving clinical outcomes prognosis. To evaluate effects Compound Kushen Injection (CKI) on its role mitigating chemotherapy-induced adverse with CRC. We retrieved randomized controlled trials (RCTs) evaluating CKI from eight Chinese English databases, up until 31 December 2024. The Cochrane Handbook was used assess quality included studies. For meta-analysis, we utilized Review Manager 5.4.1 software. Sensitivity analysis publication bias assessment were conducted using Stata 17.0 A total 2,663 (1,550 males 1,113 females) 30 RCTs included. Compared conventional chemotherapy (CC), combination CC significantly enhanced function, increasing CD3+ levels (MD = 6.15, 95% CI: 4.78 7.53, p < 0.00001), CD4+ 8.05, 6.99 9.11, CD4+/CD8+ 0.36, 0.28 0.44, NK cell 3.60, 2.85 4.34, while reducing CD8+ -4.19, -5.11 -3.27, 0.00001). also improved objective response rate (ORR, RR 1.50, 1.38 1.62, 0.00001) disease control (DCR, 1.15, 1.10 1.19, decreased CEA -1.79, -2.81 -0.76, 0.0007) CA199 -0.73, -1.35 -0.12, 0.02), reduced reactions, including nausea, vomiting, hepatic dysfunction, myelosuppression, neurotoxicity, leukopenia, thrombocytopenia, mouth ulcers. Current evidence suggests that may have beneficial ORR, DCR, reactions patients. However, given variability study absence stage stratification, these findings should be interpreted caution. Furthermore, lack long-term follow-up data limits understanding CKI's impact survival life. High-quality, large-scale extended are needed further efficacy, safety, applicability management. https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=632516, identifier CRD42025632516.

Язык: Английский

Процитировано

0